StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
ERASBullishIndustry Newsnews
High materiality8/10

Erasca's ERAS-0015 Shows 57% uORR in 2L+ PDAC, 2027 Pivotal Plans.

Jul 13, 2026, 4:04 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Strong early signals (57% uORR at 32 mg QD, 100% RDI, no DLTs) validate monotherapy potential and de-risk the therapeutic approach; coupled with rapid progression to registration-enabling trials in NSCLC and PDAC, near-term catalysts could lift ERAS shares. Risk includes trial readouts not meeting endpoints and dilution needs.

AI summary

What happened, with direct paths to the underlying reporting

ERAS-0015 in 2L+ KRAS G12X PDAC shows 57% uORR8wk at 32 mg QD with 100% RDI and no DLTs, signaling robust monotherapy activity. Early panitumumab data in CRC suggests combo potential; management plans to initiate registration-enabling NSCLC and PDAC trials in 2027, with readouts expected in the first half of 2027.

  • 57% uORR8wk at 32 mg QD in 2L+ KRAS G12X PDAC.
  • No DLTs; monotherapy generally well-tolerated at RDEs.
  • Panitumumab combo shows no DLTs in 16 mg cohort.
  • Plans include registrational trials in NSCLC and PDAC in 2027; readouts H1 2027.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event